Sign In
Buy INMB
$2.09
+0.180 (+9.42%)
At Close: Aug 07, 2026
INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
09:00am, Monday, 12'th Feb 2024
Boca Raton, Florida, Feb. 12, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation
INmune Bio to Participate in Baird's Biotech Discovery Series Webcast on February 13, 2024
09:00am, Tuesday, 06'th Feb 2024
Boca Raton, Florida, Feb. 06, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammat
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer's Disease Program
08:00am, Tuesday, 30'th Jan 2024
The Phase II clinical trial in patients with Alzheimer's disease with neuroinflammation is on track to complete enrollment mid-2024 with top line data expected approximately six months after the final
Boca Raton, Florida, Jan. 02, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the p
Enrollment in the Company's Phase II study using XPro TM to treat patients with Alzheimer's Disease with neuroinflammation is accelerating in sites outside the US and the Company is maintaining its ti
Alzheimer's Disease Drug Development: Another Lost Year
03:58am, Tuesday, 05'th Dec 2023
Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of
7 Earnings Losers to Load Up On Right Now
08:28pm, Sunday, 05'th Nov 2023
Generally speaking, earnings losers represent exactly that – companies that failed to deliver against established targets. Just like in sports, you don't get points for missing the shot or not going
INmune Bio, Inc. (INMB) Q3 2023 Earnings Call Transcript
10:38pm, Wednesday, 01'st Nov 2023
INmune Bio, Inc. (NASDAQ:INMB ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants David Moss - Chief Financial Officer RJ Tesi - Chief Executive Officer Mark Lowdell -
INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7
08:00am, Monday, 31'st Jul 2023
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage im
INmune Bio's Alzheimer's treatment merits a high-upside price target, analysts say
02:26pm, Friday, 02'nd Jun 2023
Analysts at Baird initiated coverage of the immunology company INmune Bio with a price target more than double its current share price. The firm issued an Outperform rating and target price of $16.
INmune Bio Inc.'s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy
09:00am, Wednesday, 24'th May 2023
BOCA RATON, Fla., May 24, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) announces that Mark Lowdell, Ph.D., INmune Bio's CSO, will be giving the opening plenary lecture of the Presidentia
INmune Bio, Inc. (INMB) Q1 2023 Earnings Call Transcript
10:00pm, Wednesday, 03'rd May 2023
INmune Bio, Inc. (NASDAQ:INMB ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants David Moss - Chief Financial Officer RJ Tesi - Chief Executive Officer Mark Lowdell - Chief
INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3
09:00am, Monday, 24'th Apr 2023
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, April 24, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage i
INmune Bio: Alzheimer's Disease Treatment Lottery Ticket
05:00am, Monday, 24'th Apr 2023
INmune Bio: Alzheimer's Disease Treatment Lottery Ticket.
Two presentations show targeting high-risk MUC4 expressing HER2+ and Triple Negative Breast Cancer with INB03 reverses resistance mechanisms to immunotherapy
